HL-60 Cells
USUSD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Summary on the HL-60 cell line
| 說明 | HL-60 cells, originating from a 36-year-old female with acute promyelocytic leukemia, serve as a vital model in cancer research, particularly in studying hematological malignancies, due to their ability to differentiate into mature white blood cells and mimic innate immune responses, aiding in the understanding of leukemic progression, cellular oncogene expression, and therapeutic target identification. The ability of HL-60 cells to differentiate into mature white blood cells, such as granulocytes and monocytes, through agents like dimethyl sulfoxide (DMSO) or retinoic acid, underscores their significance in studies related to human myeloid cell differentiation and sheds light on the mechanisms underpinning leukemic progression and the efficacy of therapeutic interventions. HL-60 human myeloid leukemia cells are integral to research focusing on apoptosis, cell activation, and the cell cycle, including the regulation of key oncogenes like the c-myc proto-oncogene and tumor necrosis factor (TNF-alpha). Their capability to form extracellular traps, structures involved in trapping and killing pathogens, which mirrors the innate immune response seen in primary neutrophils, makes HL-60 cells a useful model for studying the immune aspects of leukemia and how leukemic cells interact with the immune system. Moreover, the responsiveness of HL-60 cells to signaling pathways such as the MAPK pathway and various kinases is crucial for dissecting the molecular mechanisms driving leukemic cell proliferation and differentiation. This aspect is particularly beneficial for identifying therapeutic targets and developing new treatment strategies for leukemia. HL-60 cells are a critical resource in cancer research, offering insights into hematological malignancies, leukemic progression, and potential therapeutic targets through their unique differentiation capabilities and mimicry of immune responses. |
|---|---|
| 生物體 | Human |
| 組織 | Blood |
| 疾病 | Acute promyelocytic leukemia |
| 應用 | Transfection host |
| 同義詞 | HL 60, HL.60, HL60 |
Characteristics
| 年齡 | 36 years |
|---|---|
| 性別 | Female |
| 族裔 | Caucasian |
| 形態學 | Round cells |
| 細胞類型 | Lymphoblast |
| 生長特性 | Suspension |
Specifications
| 引用 | HL-60 (Cytion catalog number 300209) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_0002 |
Genetics of the promyelocytic leukemia cell line HL-60
| 受體的表達 | Complement, Fc |
|---|---|
| 同工酶 | G6PD, B, PGM1, 1, PGM3, 1, ES-D,1, Me-2, 1, AK-1, 1, GLO-1, 1 |
| 致癌基因 | Myc+ |
| 逆轉錄酶 | Negative |
| 產品 | Tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid |
Handling
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% heat-inactivated FBS |
| 傳代培養 | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| 播種密度 | 2 x 105 cells/ml |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality control
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 300209-040325 | 分析證明書 | 23. May. 2025 | 300209 |
| 300209-221223 | 分析證明書 | 23. May. 2025 | 300209 |